What BMI Do You Need for GLP-1 Coverage? The Real Criteria

You've been told a GLP-1 medication could help you — but your insurance keeps asking for your BMI before it will approve anything.

It's frustrating, especially when the number on the scale feels beside the point.

Here's the good news: the BMI thresholds insurers use are well-defined, and there's a lower-BMI path most people never hear about.

In this guide, you'll learn exactly which BMI numbers trigger coverage, how a documented health condition can qualify you at a lower BMI, and what to do if your plan denies you anyway.

Specifically, you'll learn:

• The two core BMI thresholds every major insurer uses
• Which comorbidities unlock the lower BMI tier
• Why documentation — not just your actual BMI — is often the deciding factor
• What to do when your plan excludes weight-loss drugs entirely
• The cash-pay and Medicare options available right now in 2026

The Two BMI Thresholds That Drive GLP-1 Coverage

Almost every commercial insurance plan that covers GLP-1 medications for weight loss uses one of two BMI cutoffs in its prior-authorization criteria.

They are not random numbers — they mirror the FDA-approved indications for drugs like Wegovy and Zepbound.

Threshold #1: BMI ≥ 30

A BMI of 30 or higher puts you in the clinical obesity range.

If your documented BMI meets this number, you clear the BMI hurdle for most plans — full stop, no additional health conditions required.

This is the cleaner, simpler path to approval.

Threshold #2: BMI ≥ 27 with at Least One Weight-Related Condition

A BMI between 27 and 29.9 — the overweight range — is where things get more nuanced.

Most plans will still approve coverage at this BMI, but only if you also have at least one documented weight-related health condition.

The qualifying conditions typically include:

• Hypertension (high blood pressure)
• Type 2 diabetes
• Dyslipidemia (high cholesterol or triglycerides)
• Obstructive sleep apnea
• Established cardiovascular disease

If you have a BMI of 28 and diagnosed hypertension, you likely meet the clinical criteria — even though your BMI alone would fall short.

Here's the bottom line:

If your BMI is below 27, standard insurance coverage for a GLP-1 as a weight-loss drug is extremely unlikely — regardless of your health history.

This article focuses on the 27-and-above range where the real coverage battles happen.

The Comorbidity Shortcut: How to Qualify at BMI 27

This is the section most people skip — and it's where a lot of unnecessary denials happen.

If your BMI is between 27 and 29.9, a single documented comorbidity can move you from "not covered" to "covered."

Let's walk through the qualifying conditions and what makes them powerful.

Cardiovascular Disease: The Strongest Lever

Wegovy has an FDA-approved indication specifically to reduce cardiovascular risk in adults with established cardiovascular disease and obesity or overweight.

This matters because cardiovascular risk reduction is a covered medical indication — not just a weight-loss framing.

If you have a history of heart attack, stroke, or established coronary artery disease, your prescriber can frame the Wegovy request around that indication instead of weight loss.

That reframing alone has changed the outcome of many prior-auth decisions.

Type 2 Diabetes: The Easiest Coverage Path

GLP-1 coverage for type 2 diabetes is near-universal across commercial insurance, Medicare, and Medicaid.

If a type 2 diabetes diagnosis applies to you, drugs like Ozempic (semaglutide) and Mounjaro (tirzepatide) are far easier to get covered — because they're approved for diabetes, not weight loss.

The weight loss follows the treatment. But the coverage is driven by the diabetes indication.

Here's what most people don't realize:

Ozempic and Mounjaro are the same molecules as Wegovy and Zepbound — just with diabetes approvals instead of weight-loss approvals.

If you have type 2 diabetes, work with your prescriber to pursue the diabetes-approved version of the drug first.

Sleep Apnea, Hypertension, and Dyslipidemia

These three conditions are the most common qualifying comorbidities for the BMI-27 tier.

Many people have at least one of them diagnosed and simply don't know it counts.

Check your chart: if you've been told your blood pressure is high, your cholesterol needs managing, or you use a CPAP machine, you may already have the comorbidity documentation you need.

Why Documentation Matters More Than Your Actual BMI

This is one of the most important concepts in this entire guide.

Your BMI might perfectly meet the threshold — but if it isn't documented in your chart at the time of the prior-auth request, the insurer will deny you.

Insurance decisions are made on paper, not on what your doctor knows about you.

What "Documented" Actually Means

For a prior-auth to succeed, your chart needs to show:

• A recorded height and weight (from which BMI is calculated) at a recent visit
• A diagnosis code for obesity (E66.x) or overweight (E66.09) tied to that BMI
• Any comorbidity listed as an active problem — not just mentioned in a note
• Prescriber attestation that the drug is medically necessary for this patient

That last point — prescriber attestation — is something your doctor's office handles. But it's worth asking whether they've included it explicitly.

The Single Most Common Avoidable Denial

A patient has a BMI of 28.5 and has been treated for hypertension for three years.

The prior-auth gets denied because the most recent office note documented the blood pressure as "well controlled" — and the hypertension diagnosis wasn't listed as an active problem on that visit.

The insurer didn't see a current comorbidity. Denied.

This is not a rare edge case. It's one of the most common denial patterns for BMI-27 patients.

The fix is simple:

Ask your prescriber to review and update your active problem list before submitting any prior-auth, and to confirm that every qualifying criterion is visible in the chart notes tied to the request.

For a full breakdown of what insurers look for line by line, read our guide to GLP-1 Prior Authorization: The Exact Requirements (and How to Meet Them).

The Other Prior-Auth Hurdles (Beyond BMI)

BMI is the headline criterion, but it's rarely the only one.

Most plans also require you to clear several additional hurdles before they'll approve a GLP-1 for weight loss.

Documented Diet and Lifestyle Effort

Most plans require evidence that you've participated in a reduced-calorie diet and increased physical activity for a defined period — often three to six months.

This doesn't mean you had to lose weight. It means your chart needs to show the effort.

Referrals to a registered dietitian, documented counseling notes, or a formal structured program all count. A brief mention in a progress note can also work.

Step Therapy (Trying a Cheaper Drug First)

Some plans require you to try and fail a preferred — usually cheaper — medication before they'll approve a GLP-1.

This requirement varies widely by plan. Some waive it. Others require it strictly.

If your plan has a step-therapy requirement, your prescriber needs to document that you tried the preferred option and it was ineffective or not tolerated.

Formulary Match

Your plan's formulary may only cover one GLP-1, not all of them.

If Wegovy is the preferred drug and your prescriber requested Zepbound, the denial may be purely formulary-based — not clinical.

Check your plan's formulary before the request goes in, or ask the prescriber's office to check. A simple switch in which drug is requested can flip a denial to an approval.

What Happens When Your Plan Denies You

A denial is not the end of the road. Most people don't know there's an appeal ladder — and that each rung has a real chance of success.

The Appeal Ladder

Here's how the process works, step by step:

• Internal Appeal #1: Submit a letter of medical necessity that ties your documented chart to each named criterion in the denial letter
• Peer-to-Peer Review: Your prescriber speaks directly with the plan's medical director — this step wins surprisingly often
• Internal Appeal #2: Submit any newly available documentation that wasn't in the original request
• External Review: A neutral, independent review organization makes the final call — this is where benefit-exclusion versus medical-necessity arguments get resolved

The peer-to-peer review step is underused. Many prior-auth denials get overturned when a prescriber has a direct conversation with the plan's medical director and walks through the clinical rationale in person.

Encourage your prescriber to request it.

When Appeals Won't Work

Here's the uncomfortable truth about benefit-exclusion denials.

Many employer-sponsored plans and most standard Medicare plans have carved out "anti-obesity medications" as an excluded benefit category entirely.

If your plan doesn't cover weight-loss drugs at all — regardless of your BMI or health history — no appeal will change that. It's a plan-design decision, not a clinical one.

When you're facing a hard exclusion, the move is to pivot — not to appeal endlessly.

Your options at that point are: reframe the request around a covered indication (cardiovascular disease, diabetes), explore a cash-pay path, or check whether you qualify for the Medicare GLP-1 Bridge.

Our full guide on what to do when insurance won't cover Wegovy for weight loss covers every pivot in detail.

And if you're pursuing a formal appeal, visit our appeals tool to build your letter of medical necessity step by step.

Cash-Pay and Medicare Paths If Insurance Won't Budge

If insurance coverage isn't happening right now, you still have real options — and the prices in 2026 are meaningfully lower than they were even a year ago.

Cash-Pay Options (As of June 2026)

Here's what each of those looks like in practice:

• Wegovy injectable: $199/mo for the first two fills (new patients, through June 30, 2026), then ~$349/mo for most doses through the Wegovy Savings Offer
• Wegovy pill (oral semaglutide): $149/mo self-pay for 1.5 mg and 4 mg doses; the 4 mg price holds through August 31, 2026, then moves to ~$199/mo
• Zepbound vials: From ~$299/mo for lower doses via LillyDirect self-pay; higher doses cost more
• Foundayo (orforglipron): $149/mo self-pay; as low as $25/mo with a commercial insurance savings card; ~$50/mo for eligible Medicare Part D members via the GLP-1 Bridge

Always verify current prices directly — these programs have expiration dates and dose-specific rules. All prices shown are as of June 2026.

Medicare: The GLP-1 Bridge Program

Standard Medicare has not historically covered GLP-1 medications for weight loss.

That changed — partially — starting July 1, 2026.

The Medicare GLP-1 Bridge is a limited, time-bound demonstration program that makes injectable Wegovy, Zepbound, Mounjaro, Ozempic, the Wegovy pill, and Foundayo available to eligible Part D members for approximately $50 per month after deductible.

Important caveats:

• This is a demonstration program, not permanent coverage
• Not every Part D plan participates
• Not every Medicare member qualifies
• Standard Medicare still does not cover GLP-1s for weight loss outside this program

If you're on Medicare and want to know whether you're eligible, visit our Medicare Bridge guide for the full eligibility breakdown.

Medicaid: It Depends on Your State

Medicaid coverage of GLP-1s for weight loss varies significantly by state.

As of 2026, at least 13 states have confirmed coverage — but three states (California, Michigan, and Pennsylvania) are confirmed to be cutting that coverage in 2026.

GLP-1 coverage for type 2 diabetes through Medicaid remains available nearly everywhere.

Check your specific state's Medicaid formulary, or use our Medicaid coverage tool to see what your state currently covers.

For a deeper look at the insurance process for Zepbound specifically, see our guide on how to get Zepbound covered by insurance in 2026.

Your Next Move

The BMI requirement for GLP-1 coverage isn't a wall — it's a threshold with two entries: BMI ≥ 30 on its own, or BMI ≥ 27 with a documented comorbidity that your prescriber has recorded in your current chart.

If your BMI qualifies but you've been denied, the problem is almost always documentation — not eligibility — and that's fixable with one good office visit and a well-prepared prior-auth submission.

And if your plan excludes weight-loss drugs entirely, the cash-pay and Medicare Bridge options in 2026 are more accessible than most people realize.

What's standing between you and coverage right now — the BMI number, the documentation, the appeal, or the cost?